Trading Options with an Edge
Select Page

Member Content

Antibody Drug Conjugates (ADCs) Platforms Could See Resurgence of Interest with Potential M&A Deal

by | Jun 30, 2022

Thematic Snapshot – Antibody Drug Conjugates (ADCs)

Biotech M&A has been an intriguing area recently, as outlined in the Quarterly Brief, and one potential deal – Merck’s $20B+ buy of SeaGen – could spark a rally or resurgence of interest in a...

Please login to continue reading this article.

Not a Member yet?
Subscribe to
OptionsHawk Premium
Subscribe

Options Hawk Max

$300 | 30 days

  • Options Hawk Trading Hub Live Chat
  • Hawk’s Market Blitz
  • Spotlight Trades (2 Per Week)
  • Market Recap
  • Weekly Earnings Snapshots
  • Live Mock Portfolio
  • 1 on 1 Access
  • Hawk’s Trader Toolbox
  • Street Research
  • OptionsHawk Research
  • Daily Options Radar
  • OptionHawk’s Weekly Radar Report
  • Options Hawk Market Outlook Access
  • Daily Earnings Grid
  • Weekly and Monthly OpEx Sheets
  • Notable Options Database
  • OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$149 | 30 days

  • Hawk’s Market Blitz
  • Spotlight Trades (2 Per Week)
  • Market Recap
  • Weekly Earnings Snapshots
  • OptionsHawk Research
  • Daily Options Radar
  • OptionHawk’s Weekly Radar Report
  • Options Hawk Market Outlook Access
  • Daily Earnings Grid
  • OptionsHawk Quarterly Market Brief

More About this Plan